Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats

被引:93
作者
Seitz, S
Boelsterli, UA
机构
[1] Swiss Fed Inst Technol, Inst Toxicol, Zurich, Switzerland
[2] Univ Zurich, CH-8006 Zurich, Switzerland
关键词
D O I
10.1016/S0016-5085(98)70026-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Enterohepatic recirculation of nonsteroidal anti-inflammatory drugs is a critical factor in the pathogenesis of intestinal injury, but the underlying mechanism of toxicity remains obscure. The aim of this study was to examine the role of diclofenac acyl glucuronide, which is the major biliary metabolite and is chemically reactive, in the precipitation of small intestinal ulceration. Methods: Hepatocanalicular conjugate export pump-deficient (TR-) rats were used to selectively block diclofenac enterohepatic circulation without interrupting bile flow. Bile from diclofenac-treated normal rats was orally transferred to wild-type and TR- rats, and the extent of ulcer formation was compared with that induced by control bile containing free diclofenac. The effect of induction of hepatic diclofenac glucuronosyltransferase on the severity of diclofenac-induced ulceration was also determined. Results: TR- rats were refractory to diclofenac given either intraperitoneally or perorally. However, transfer of bile containing diclofenac glucuronide significantly increased the extent of ulcer formation in both normal and TR- rats. Moreover, induction of glucuronosyltransferase aggravated intestinal ulceration. Conclusions: The reactive acyl glucuronide of diclofenac, or the acyl glucuronide of one of its oxidative metabolites, is directly involved in the pathogenesis of small intestinal injury.
引用
收藏
页码:1476 / 1482
页数:7
相关论文
共 49 条
[21]   DICLOFENAC COVALENT PROTEIN-BINDING IS DEPENDENT ON ACYL GLUCURONIDE FORMATION AND IS INVERSELY RELATED TO P450-MEDIATED ACUTE CELL INJURY IN CULTURED RAT HEPATOCYTES [J].
KRETZROMMEL, A ;
BOELSTERLI, UA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1993, 120 (01) :155-161
[22]  
KRETZROMMEL A, 1994, MOL PHARMACOL, V45, P237
[23]  
Le H T, 1996, J Biochem Toxicol, V11, P297, DOI 10.1002/(SICI)1522-7146(1996)11:6<297::AID-JBT5>3.3.CO
[24]  
2-S
[25]   Selective induction of phase II drug metabolizing enzyme activities by quinolines and isoquinolines [J].
Le, HT ;
Franklin, MR .
CHEMICO-BIOLOGICAL INTERACTIONS, 1997, 103 (03) :167-178
[26]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND THE GASTROINTESTINAL-TRACT - THE DOUBLE-EDGED-SWORD [J].
LICHTENSTEIN, DR ;
SYNGAL, S ;
WOLFE, MM .
ARTHRITIS AND RHEUMATISM, 1995, 38 (01) :5-18
[27]  
McGurk KA, 1996, DRUG METAB DISPOS, V24, P842
[28]   Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene [J].
Paulusma, CC ;
Bosma, PJ ;
Zaman, GJR ;
Bakker, CTM ;
Otter, M ;
Scheffer, GL ;
Scheper, RJ ;
Borst, P ;
Elferink, RPJO .
SCIENCE, 1996, 271 (5252) :1126-1128
[29]   PHARMACOKINETICS AND BIOAVAILABILITY OF DICLOFENAC IN THE RAT [J].
PERISRIBERA, JE ;
TORRESMOLINA, F ;
GARCIACARBONELL, MC ;
ARISTORENA, JC ;
PLADELFINA, JM .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (06) :647-665
[30]   IMMUNOCHEMICAL DETECTION OF LIVER PROTEIN ADDUCTS OF THE NONSTEROIDAL ANTIINFLAMMATORY DRUG DICLOFENAC [J].
PUMFORD, NR ;
MYERS, TG ;
DAVILA, JC ;
HIGHET, RJ ;
POHL, LR .
CHEMICAL RESEARCH IN TOXICOLOGY, 1993, 6 (02) :147-150